EVT Execute
Drug discovery services
Target identification and validation
Hit identification
Sample management
Chemistry
DMPK and ADME-Tox
Research informatics and in silico drug discovery
Proteomics and metabolomics
Bio-reagents
In vitro biology
In vivo pharmacology
Biomarkers
Antibody platform
INDiGO
Integrated CMC
Therapeutic areas
Anti-infectives
Immunology and inflammation
Metabolic diseases and complications
Neurosciences
Oncology
Respiratory
Integrated drug discovery
EVT Execute alliances
Science pool
Scientific publications
Resources
Business Development Events
EVT Innovate
Pipeline of product opportunities
Pharma partnerships
R&D projects
iPSC platform
Spin-offs and other holdings
BRIDGES
DDup
Career
Invest
Stock information
News
Financial publications
IR Events
Annual General Meeting
Annual General Meeting Archive
Corporate Governance
About
Evotec worldwide
History
Management
Supervisory Board
Imprint
DE
EN
Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter
Our recent
collaboration with Massachusetts General Hospital (MGH)
on the identification and validation of novel targets in Gram-negative bacteria is covered in the
Spring edition of OneNucleus Newsletter
.
Read the full article on page 8 with our expert, Antonio Felici.